

## Intervet International bv

[View the current Intervet International bv Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/24768-Intervet+International+bv.html)

(<http://www.bioportfolio.com/bi corporate/24768-Intervet+International+bv.html>)

### Contact Details:

**Wim de Körverstraat 35**  
**AN Boxmeer**

Tel: 31 (0) 485 587600  
Fax: 31 (0) 485 577333  
Email:

**5831**  
**Netherlands**

Intervet Inc. is the U.S. operating division of Intervet International, the world's third leading animal health company.

Our company is a leader in research and development of veterinary vaccines and pharmaceutical products. Our portfolio includes vaccines for use in pets, livestock, poultry and aquaculture; antiparasitics, anti-infectives, endocrine products, diagnostics, feed additives and productivity enhancers.

We have more than 4,800 employees worldwide and maintain a global distribution network of subsidiary companies and agents in 120 countries.

Intervet is a division of Akzo Nobel and maintains its US headquarters in Millsboro, Delaware, and its international headquarters in Boxmeer, The Netherlands.

Intervet Inc. is an animal health company focused on three objectives:

1. Discovering, producing and marketing quality products to make animals healthier and more productive
2. Providing innovative and profitable business solutions to our veterinary, production and distribution clients

### Recent Publications by Intervet International bv:



- [Dose and timing requirements for immunogenicity of viral poultry vaccine antigen: investigations of emulsion-based depot function.](#)  
*The release requirements for vaccine antigens delivered by adjuvants with...* 15th December, 2007  
Department of Vaccine Technology and Immunology R&D, OrganonBioSciences,- Avian Pathol. 2007 Oct;36(5):361-5. ([DOI Direct Link](#))
- [Vaccine immunopotentiators of the future.](#)  
*Vaccine adjuvants or immunopotentiators comprise a diverse group of...* 7th December, 2007  
Department of Vaccine Technology and Immunology R&D, Intervet- Clin Pharmacol Ther. 2007 Dec;82(6):750-5. Epub 2007 Oct 3. ([DOI Direct Link](#))

- [Vaccination against large Babesia species from dogs.](#)  
*The original observation of Sibiric that soluble parasite antigens (SPA)...*6th December, 2007  
Parasitology R&D Department, Intervet International BV Boxmeer, The- Parassitologia. 2007 May;49  
Suppl 1:13-7.
- [Tight control of transcription in Toxoplasma gondii using an alternative tet repressor.](#)  
*Fusion of yellow fluorescent protein (YFP) to the N-terminus of the...*21st February, 2007  
Department of Parasitology R and D, Intervet International BV, P.O. Box- Int J Parasitol. 2006  
Apr;36(4):443-52. Epub 2006 Feb 13. ([DOI Direct Link](#))
- [BoHV-1 eradication--one step closer.](#)  
*The original observation of Sibiric that soluble parasite antigens (SPA)...*12th January, 2007  
Intervet International- Berl Munch Tierarztl Wochenschr. 2006 Nov-Dec;119(11-12):516-20.
- [The complete set of Toxoplasma gondii ribosomal protein genes contains two conserved promoter elements.](#)  
*Recently we showed that de novo ribosome biosynthesis is transcriptionally...*6th October, 2006  
Department of Parasitology R&D, Intervet International BV, P.O. Box 31,- Parasitology. 2006 Jul;133(Pt  
1):19-31. Epub 2006 May 4. ([DOI Direct Link](#))
- [Vaccine potential of recombinant Ornithobacterium rhinotracheale antigens.](#)  
*Ornithobacterium rhinotracheale is a pathogen involved in respiratory...*2nd August, 2006  
Intervet International BV, Bacteriological R&D, Boxmeer, The Netherlands.- Vaccine. 2006 Mar  
10;24(11):1858-67. Epub 2005 Oct 24. ([DOI Direct Link](#))
- [Successful selection of cross-protective vaccine candidates for Ornithobacterium rhinotracheale infection.](#)  
*Ornithobacterium rhinotracheale is a bacterial pathogen known for causing...*13th December, 2005  
Intervet International BV, Bacteriology R&D, Boxmeer, The Netherlands.- Infect Immun. 2005  
Oct;73(10):6812-21. ([DOI Direct Link](#))
- [Potentiation of humoral immune responses to vaccine antigens by recombinant chicken IL-18 \(rChIL-18\).](#)  
*Mammalian interleukin-18 (IL-18) is one of the pro-inflammatory cytokines...*28th October, 2005  
Intervet International BV, Department of Vaccine Technology and Immunology- Vaccine. 2005 Jul  
21;23(33):4212-8. ([DOI Direct Link](#))
- [Passive immunization of immune-suppressed animals: chicken antibodies protect against Ornithobacterium rhinotracheale infection.](#)  
*Unravelling of the protective immunity acquired during a natural infection...*20th September, 2005  
Intervet International BV, Bacteriology R&D, Wim de Korverstraat 35,- Vaccine. 2005 May  
16;23(26):3404-11. ([DOI Direct Link](#))
- [The pharmacokinetics of vedaprofen and its enantiomers in dogs after single and multiple dosing.](#)  
*Vedaprofen is a chiral nonsteroidal anti-inflammatory drug that has been...*12th August, 2005  
Intervet International bv, Boxmeer, the Netherlands.- J Vet Pharmacol Ther. 2005 Jun;28(3):305-12. (  
[DOI Direct Link](#))
- [Vaccine adjuvant technology: from theoretical mechanisms to practical approaches.](#)  
*Poorly immunogenic antigens depend on vaccine adjuvants to evoke an immune...*2nd August, 2005  
Dept. Vaccine Technology & Immunology R & D, Intervet International BV,- Dev Biol (Basel).  
2005;121:127-34.
- [Th1/Th2 polarization by viral and helminth infection in birds.](#)  
*Mammals developed an immune system able to functionally polarize into...*13th July, 2005  
Department of Vaccine Technology and Immunology, Intervet International- Vet Microbiol. 2005 Feb  
25;105(3-4):163-7. ([DOI Direct Link](#))
- [De novo ribosome biosynthesis is transcriptionally regulated in Eimeria tenella, dependent on its life cycle stage.](#)  
*Protozoan parasites go through various developmental stages during their...*22nd April, 2005  
Department of Parasitology, Intervet International BV, P.O. Box 31, 5830AA- Mol Biochem Parasitol.  
2005 Feb;139(2):239-48. ([DOI Direct Link](#))
- [Minor species, who cares?](#)

**Press Releases on Intervet International bv:**

["As an Industry, We've Been too Focused on Regulatory Approval," Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.](#)

26th November, 2009

LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes

[SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors](#)

25th November, 2009 SCAN Health Plan

LONG BEACH, Calif., Nov. 25 /PRNewswire/ -- Thanksgiving meals will be delivered to approximately 1,000 homebound seniors in the greater Long Beach area thanks to Faith In Action/Volunteer Action for

[Video: Genworth Recognizes the Nation's Caregivers in New Ad Campaign](#)

25th November, 2009 Genworth Financial

RICHMOND, Va., Nov. 25 /PRNewswire-FirstCall/ -- There are 120 million reasons to recognize caregivers in the U.S., and Genworth Financial (NYSE: GNW) will celebrate and give thanks to these men and

[Winner Medical to Present at the Piper Jaffray 21st Annual Health Care Conference on Tuesday December 2](#)

25th November, 2009 Winner Medical Group Inc.

SHENZHEN, China, Nov. 25 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Amex: WWIN; "Winner Medical", or the "Company"), a leading manufacturer and exporter of medical, wound

[Swissray International Announces New Ownership](#)

25th November, 2009 Swissray International, Inc.

EAST BRUNSWICK, N.J., Nov. 25 /PRNewswire/ -- Swissray International, Inc. a leading manufacturer of direct digital Radiography (ddR) systems, announced today that its operations have been acquired by

**BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

